Merck reports mixed data for Lucentis competitor in diabetic macular edema

Data ReadoutMixedremigromigLucentisNeutral

AI Analysis

Summary

Merck's remigromig met the primary endpoint in a pivotal study for diabetic macular edema, demonstrating non-inferiority to Lucentis, though full results raise concerns about commercial viability.

Clinical Trial Data

Phase

pivotal

Primary Endpoint

Met

Outcome Details

Met primary endpoint but raises questions about commercial prospects

Importance:6/10

Sentiment:

0.10

ophthalmologydiabetic macular edemaPhase 3clinical trialremigromig

Related Companies

$MRK

Read the original article

Published by Endpoints News on October 12, 2026 6:18 PM

Read Original